Joinn Laboratories (China) Co (HKSE:06127) 3-Year EPS without NRI Growth Rate : -1.20% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co 3-Year EPS without NRI Growth Rate?

Joinn Laboratories (China) Co's EPS without NRI for the three months ended in Dec. 2023 was HK$-0.03.

During the past 12 months, Joinn Laboratories (China) Co's average EPS without NRI Growth Rate was -66.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was -1.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 37.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 31.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Joinn Laboratories (China) Co was 75.70% per year. The lowest was -1.20% per year. And the median was 30.30% per year.

Competitive Comparison of Joinn Laboratories (China) Co's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Joinn Laboratories (China) Co's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's 3-Year EPS without NRI Growth Rate falls into.

Joinn Laboratories (China) Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Joinn Laboratories (China) Co (HKSE:06127) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Joinn Laboratories (China) Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (HKSE:06127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

603127:China

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Joinn Laboratories (China) Co (HKSE:06127) Headlines

No Headlines